I am head of the nuclear medicine physics section, which supports research in PET/CT, targeted therapies, and molecular imaging. As both a medical and biophysicist, I investigate nuclear imaging methodologies to define tumor targets in terms of their metabolic and microenvironmental properties. I have a special interest in the quantitative imaging of tumor hypoxia — a known factor in determining resistance to treatment — and in ways of precisely delivering radiotherapy to a tumor, including targeting radionuclides using antibodies that can home in on cancer cells to provide a diagnostic image as well as deposit a therapeutic dose.
- Bartlett RM, Beattie BJ, Naryanan M, Georgi JC, Chen Q, Carlin SD, Roble G, Zanzonico PB, Gonen M, O’Donoghue J, Fischer A, Humm JL. Image-guided PO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats. J Nucl Med. 2012 Oct;53(10):1608-15. doi: 10.2967/jnumed.112.103523. Epub 2012 Aug 29.
- McCall KC, Humm JL, Bartlett R, Reese M, Carlin S. Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia. Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e393-9. doi: 10.1016/j.ijrobp.2012.05.005. Epub 2012 Jun 23.
- Loevinger-Berman Award, Society of Nuclear Medicine and Molecular Imaging (2012)
- Fellow, American Association of Physicists in Medicine (2007)